Quantification of circulating Epstein–Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance

SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group

(2012) Y.-L. Kwong et al.   BLOOD

Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal Type

(2012) Y. Ito et al.   CLINICAL CANCER RESEARCH

Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type

(2011) R. Suzuki et al.   BLOOD

Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study

(2011) Motoko Yamaguchi et al.   JOURNAL OF CLINICAL ONCOLOGY

Diagnosis and management of natural killer-cell malignancies

(2010) Fumihiro Ishida et al.   Expert Review of Hematology

Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma

(2009) Hyo Song Kim et al.   LEUKEMIA & LYMPHOMA

Phase I study of dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia

(2008) Motoko Yamaguchi et al.   CANCER SCIENCE